American Society of Hematology

Fig. 3.

$Fig. 3. Reverse transcription of Brome Mosaic Virus (BMV) RNA by sucrose gradient fractionated platelet lysate. (A) shows the density profile of a sucrose gradient fractionation of a platelet lysate made from patient UPN08. (B) and (C) show the result of a reverse transcriptase assay performed on fractions from the gradient. (B) Lanes are (from left to right) M, marker; *, no BMV RNA control; −, no reverse transcriptase control; 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, sucrose fraction numbers. (C) Lanes are (from left to right) M, marker; 1 and 2, 2.0 U; 3 and 4, 0.2 U; 5 and 6, 0.02 U; 7 and 8, 0.002 U; 9 and 10, 0.0002 U of Moloney murine leukemia virus reverse transcriptase, respectively. “*” and “−” are as for (B).$

Reverse transcription of Brome Mosaic Virus (BMV) RNA by sucrose gradient fractionated platelet lysate. (A) shows the density profile of a sucrose gradient fractionation of a platelet lysate made from patient UPN08. (B) and (C) show the result of a reverse transcriptase assay performed on fractions from the gradient. (B) Lanes are (from left to right) M, marker; *, no BMV RNA control; −, no reverse transcriptase control; 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, sucrose fraction numbers. (C) Lanes are (from left to right) M, marker; 1 and 2, 2.0 U; 3 and 4, 0.2 U; 5 and 6, 0.02 U; 7 and 8, 0.002 U; 9 and 10, 0.0002 U of Moloney murine leukemia virus reverse transcriptase, respectively. “*” and “−” are as for (B).

This Feature Is Available To Subscribers Only